REG - IXICO plc - Consortium Agreement in Huntington's Disease

IXICOAnnouncement

10/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220510:nRSJ8537Ka&default-theme=true

RNS Number : 8537K  IXICO plc  10 May 2022

10 May 2022

 

IXICO plc

("IXICO" or the "Company")

 

Consortium agreement in Huntington's disease worth circa £0.9 million

 

IXICO plc (AIM: IXI), the neuroimaging Contract Research Organisation (CRO)
delivering advanced AI analytical insights in neuroscience, is pleased to
announce it has entered a multi-party consortium for the development of
improved imaging biomarkers for the early detection and staging of
Huntington's disease ('HD').  HD is a rare, inherited disease that causes the
progressive breakdown of nerve cells in the brain affecting movement, mood and
thinking abilities.

 

The consortium will develop new standards for HD image analysis on existing HD
image datasets.  IXICO will deliver this analysis to the biopharma and
charitable foundation consortia members using its proprietary, deep learning
based, IXIQ.Ai analysis platform.

 

This contract is for circa £0.9 million revenues which are expected to be
delivered within 2022.

 

The output of the project will enable current and future consortium partners
to develop improved approaches to stratifying patients in HD clinical trials
as well as increasing the precision of efficacy measurements of drugs within
HD clinical trials.  IXICO will seek additional partners to join the
consortium in due course.

 

Giulio Cerroni, Chief Executive Officer of IXICO, commented: "There are no
existing approved disease modifying therapies for HD, nor interventions that
slow disease progression. Consequently, we are very excited to initiate this
consortium and look forward to working closely with our founding partners in
the development of novel imaging tools that enable the design of more
efficient HD clinical trials. Applying the latest image analysis and
artificial intelligence techniques to this large dataset of HD natural history
data, will enable us to create new insights and standards towards the
implementation of precision medicine approaches in HD trials that we expect to
be of great value to the HD community.

 

This consortium agreement further cements IXICO's position as the leading
analysis company for HD as part of its wider portfolio of leading analytical
tools to support clinical trials into neurological diseases."

 

For further information please contact:

 

 IXICO plc                                         +44 (0)20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                         +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough machine learning Ai data
analytics, at scale, through its remote access TrialTracker technology
platform, to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for the Company's pharmaceutical
clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com) and
follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTSSFFWUEESEEI